Publications by authors named "A Ramiro"
Article Synopsis
- Since 2017, combining targeted therapies with traditional chemotherapy has led to better outcomes for acute myeloid leukemia (AML) patients.
- A study of 5,359 AML patients over 20 years used data from the HARMONY Alliance to analyze treatment outcomes during four 5-year periods from 1997 to 2016.
- Results show significant improvements in 5-year survival rates and reduced 60-day mortality (from 13.0% to 4.7%), even across different genetic risk groups, indicating that the advancements in treatment have positively affected patient outcomes.
Atherosclerosis is a chronic inflammatory disease of the arteries that can lead to thrombosis, infarction and stroke, underlying the first cause of mortality worldwide. Adaptive immunity plays critical roles in atherosclerosis, and numerous studies have ascribed both atheroprotective and atherogenic functions to specific subsets of T and B cells. However, less is known on how antigen specificity determines the protective or adverse outcome of such adaptive responses.
View Article and Find Full Text PDFArticle Synopsis
- Primary Sjögren's syndrome (pSS) is an autoimmune disorder influenced by type I and II interferons, with an inadequate focus on the role of innate immune cells like NK and dendritic cells.
- Researchers found a specific NK cell subset in pSS patients that is more effective at killing cells and detected higher levels of a certain type of dendritic cell (cDC2) involved in inflammation.
- The study suggests that the interaction between these NK cells and cDC2s, along with specific signaling pathways, plays a key role in pSS development, highlighting potential new targets for therapy.
Diffuse large B cell lymphoma (DLBCL) is the most common aggressive B cell lymphoma and accounts for nearly 40% of cases of B cell non-Hodgkin lymphoma. DLBCL is generally treated with R-CHOP chemotherapy, but many patients do not respond or relapse after treatment. Here, we analyzed the therapeutic potential of the tumor suppressor microRNA-28 (miR-28) for DLBCL, alone and in combination with the Bruton's tyrosine kinase inhibitor ibrutinib.
View Article and Find Full Text PDFGerminal centers (GCs) are the sites of secondary antibody diversification and underlie the mechanism of action of many vaccination strategies. Activation-induced deaminase (AID) triggers secondary antibody diversification through the introduction of somatic changes in immunoglobulin genes which lead to the generation of antibodies of higher affinity and more specialized effector functions. However, AID can also target other genomic regions, giving rise to mutations and chromosome translocations with oncogenic potential.
View Article and Find Full Text PDF